Screening v monitoring, page-2

Actually the market for breast monitoring is significant . After being treated for breast cancer the cost of monitoring to detect reoccurrence is substantial and fully claimable against medicare and insurers . No doubt as confidence in this is attained then screening would be a distinct marketable possibility in the future . IIQ has already proven high efficacy and sensitivity for early and later stage breast cancer. I think with ovarian cancer they are looking at both monitoring and detection with the later probably of greater need due to recovery rates being poor. With results due on a 200 patient trial confirmed to be completed this year together with a couple of other milestones to be announced it will be an interesting YE. DW clearly has big plans for the company and as he pointed out with him being the second highest shareholder he has a shared SP interest .